Enrollment Begins in Cytori U.S. Phase III/Pivotal Scleroderma Trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Roth Capital Cuts Price Target on Cytori Therapeutics (CYTX) Following 2Q Earnings Report
August 10, 2015 7:56 AM EDTRoth Capital reiterated a Buy rating on Cytori Therapeutics, Inc. (NASDAQ: CYTX), and cut the price target to $4.00 (from $6.00), following the company's 2Q15 earnings release. EPS of $0.03 beat the consensus estimates of -$0.03. CYTX ended the quarter with $23.8 million in cash.
Analyst Joseph Pantginis... More
Cytori Therapeutics (CYTX) Tops Q2 EPS by 6c
August 6, 2015 4:38 PM EDTCytori Therapeutics (NASDAQ: CYTX) reported Q2 EPS of $0.03, $0.06 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $1.61 million versus the consensus estimate of $2.5 million.
For earnings history and earnings-related data on Cytori Therapeutics (CYTX) click here.
... More